SCHEMBL25873244

SCHEMBL25873244

CN1CCCC(S(=O)(=O)O)C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
GABRA1 P14867 1/20 0.40
TSHR P16473 1/20 0.40
GABRG2 P18507 1/20 0.40
NFKB1 P19838 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRA6 Q16445 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
SMYD3 Q9H7B4 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
ATM Q13315 1/20 0.34
CYP2D6 P10635 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28259954 0.98 SMN1; SMN2 (0.40) LMNACYP3A4GABRA1TSHRGABRG2
SCHEMBL25873256 0.92 LMNA (0.38) LMNACYP3A4GABRA1TSHRGABRG2
SCHEMBL13621103 0.87 LMNA (0.43) LMNACYP3A4GABRA1TSHRGABRG2
Hydrochloric Acid SCHEMBL28261316 0.85 LMNA (0.41) LMNACYP3A4GABRA1TSHRGABRG2
SCHEMBL25040749 0.81 SMN1; SMN2 (0.35) LMNASMN1; SMN2SMYD3L3MBTL1ATM
SCHEMBL8320328 0.81 SMN1; SMN2 (0.35) LMNASMN1; SMN2SMYD3L3MBTL1ATM
SCHEMBL25041101 0.81 SMN1; SMN2 (0.35) LMNASMN1; SMN2SMYD3L3MBTL1ATM
SCHEMBL25040313 0.79 APLNR (0.39) SMN1; SMN2SMYD3L3MBTL1ATM
SCHEMBL25038513 0.79 APLNR (0.39) SMN1; SMN2SMYD3L3MBTL1ATM
SCHEMBL24027196 0.79 SMN1; SMN2 (0.34) SMN1; SMN2SMYD3L3MBTL1ATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
WO-2023141301-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS LMNA 1681/4885CYP3A4 1291/4885GABRA1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.